1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. RDD Pharma Acquires Naia Pharmaceuticals

M&A Deal Summary

RDD Pharma Acquires Naia Pharmaceuticals

On November 13, 2019, RDD Pharma acquired life science company Naia Pharmaceuticals

Acquisition Highlights
  • This is RDD Pharma’s 1st transaction in the Life Science sector.
  • This is RDD Pharma’s 1st transaction in the United States.

M&A Deal Summary
Date 2019-11-13
Target Naia Pharmaceuticals
Sector Life Science
Buyer(s) RDD Pharma
Deal Type Add-on Acquisition
Advisor(s) Dorsey & Whitney (Legal)

Target

Naia Pharmaceuticals

United States
Naia Rare Diseases is a development-stage biopharmaceutical company developing novel drugs for rare gastrointestinal disorders. The company is pursuing three development programs including NB 1001 for Adult SBS, NB 1001 for pediatric SBS and NB 1002, a GLP-2 agonist, for an undisclosed orphan gastrointestinal indication.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

RDD Pharma

New York, New York, United States
Category Company
Sector Life Science
DESCRIPTION

RDD Pharma Ltd. is a privately-held biopharmaceutical company focused on orphan and innovative therapies for gastrointestinal disorders. RDD Pharma Ltd. has two clinical-stage products that serve significant unmet needs. RDD-0315 is currently in Phase 2 development for the treatment of fecal incontinence in spinal cord injury patients. RDD-0315 has received Orphan Drug status in the E.U. and Fast Track designation in the U.S. RDD-1609 is being developed for the treatment of Pruritus Ani.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2019 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal